Treatment assessment
Regimen-specific checks with the NCCP criteria and reasoning alongside the result.
iPhone use: open this application from a normal Safari web address or add it to the Home Screen. The Mail/Files preview may display the interface without running its decision engine.
From clinic to home
Operationalising NCCP protocols at the point of care.
Connecting treatment assessment, clinical knowledge and clear patient information throughout the cancer treatment journey.
Find a treatment regimen
Results update as you type. Press Enter to jump to the first match or / to focus search.
One regimen. A connected pathway.
Find a regimen above, then open the support you need. Available resources vary by regimen.
Clinic workflow
Clinical knowledge, consent drafts, supportive care and NCCP source documents in one place.
Patient platform
Visual treatment information, practical guidance and timelines to help patients know what to expect.
Monitoring and milestones
Expected blood tests, scans and other checks mapped across the stages of treatment.
Do not enter identifying patient information. Verify the current NCCP protocol and apply clinical judgement.
Haematology SACT
Multiple Myeloma core library
Fifteen protocols linked to official NCCP sources use the shared SACTCheck assessment engine. Any relevant single value can be assessed and missing fields remain unassessed.
15plasma cell protocols
Validation boundary: these encodings remain pending independent Consultant Haematologist and haematology-pharmacy validation. They are not authorised to clear treatment.
Plasma cell disorders
Proteasome inhibitor, IMiD, daratumumab and oral SACT protocols.
Lymphoma
Reserved for a later independently validated batch.
Leukaemia and myeloid neoplasms
Reserved for a later independently validated batch.
Regimen information hub
Solid Tumour SACT library
Find the exact regimen, then open the clinical workflow, patient guide, source material or sustainability support you need.
v0.84.22 · What changed?
Five new breast suites, five retrospective upgrades
Source-reconciled assessments connect treatment rationale, clinician evidence, patient information, consent and supportive care. New routes and schedules include oral vinorelbine, continuous lapatinib with capecitabine breaks, and phase-specific heart monitoring. Independent clinical and pharmacy review remains pending.
Developer tools
Browse by tumour site
Each tissue page carries a stable icon and colour throughout its catalogue section. Search still covers the entire library.
BREAST LIBRARY
Find the treatment context
These filters organise the catalogue; they do not determine treatment eligibility. General chemotherapy cards remain under “receptor-unrestricted / not specified”. Maintenance is a treatment phase, and may also appear under its disease setting.
Breast · Gynaecology · Lung · GU
Weekly paclitaxel
NCCP 00226 · Version 9
PACLitaxel 80 mg/m² on days 1, 8, 15 and 22 of a 28-day cycle.
Assessment availableClinical validation pending
Gastrointestinal
Modified FOLFOX-6
NCCP 00209 · Version 10a
Longitudinal blood-count tracking and component-specific dose modification.
Assessment availableClinical validation pending
Gastrointestinal
FOLFIRI
NCCP 00227 · Version 9
Irinotecan and 5-FU dose levels, delayed-count nadirs, diarrhoea, stomatitis, renal and hepatic rules.
Assessment availableClinical validation pending
Gynaecology
Carboplatin and paclitaxel
NCCP 00303 · Version 6
21-day regimen with carboplatin renal checks, hepatic paclitaxel dosing and neuropathy pathways.
Assessment availableClinical validation pending
Gynaecology
Carboplatin + pegylated liposomal doxorubicin
NCCP 00624 · Version 3
Platinum-sensitive relapse with haematology, hepatic, PPE, stomatitis and cardiac review pathways.
Assessment availableClinical validation pending
Gynaecology
Mirvetuximab soravtansine
Local/current source required
No current NCCP SACT regimen was located in the official gynaecology library. Add once the approved local or NCCP protocol is supplied.
Catalog only
Gastrointestinal
XELOX
NCCP 00321 · Version 9
Mixed IV and oral regimen with count nadirs, renal adjustment, hand-foot syndrome, diarrhoea, stomatitis and oxaliplatin neuropathy rules.
Assessment availableClinical validation pending
Gastrointestinal
FOLFIRINOX
NCCP 00329 · Version 9
Metastatic pancreatic cancer regimen with haematology, renal, hepatic, diarrhoea, stomatitis and oxaliplatin neuropathy rules.
Assessment availableClinical validation pending
Gastrointestinal
Modified FOLFIRINOX
NCCP 00515 · Version 7
Pancreatic cancer regimen with occurrence-based blood-count and component-specific dose modification.
Assessment availableClinical review pending
Gastrointestinal
Gemcitabine and cisplatin
NCCP 00383 · Version 8
Day 1/day 8 assessment with gemcitabine percentage dosing and cisplatin renal branching.
Assessment availableClinical review pending
Gastrointestinal
Cisplatin and 5-FU chemoradiation
Herskovic · NCCP 00460 · Version 4
Oesophageal chemoradiation with haematology, renal, hepatic and toxicity criteria.
Assessment availableClinical review pending
Lung
Pembrolizumab, pemetrexed and carboplatin
NCCP 00568 · Version 5
First-line metastatic non-squamous NSCLC without EGFR or ALK-positive mutations.
Assessment availableClinical review pending
Lung
Durvalumab maintenance
NCCP 00655 · Version 3a
Durvalumab 1500 mg every 28 days after concurrent platinum-based chemoradiation for Stage III NSCLC.
Assessment availableClinical review pending
Lung
Carboplatin and etoposide
NCCP 00271 · Version 6
21-day regimen for extensive-stage small-cell lung cancer, with IV or IV/oral etoposide schedules.
Assessment availableClinical review pending
Tissue by tissue source reconciliation
Validate every regimen systematically before independent review
This workspace provides a structured primary clinical review across every enabled protocol and every tissue context in which a shared protocol is used. Each review is compared with the current NCCP source and recorded domain by domain.
Purpose: identify discrepancies early, document corrections clearly and create a reproducible record that can later support consultant oncology and oncology pharmacy validation.
Review the sourceOpen the complete current NCCP protocol for every regimen.
Review the contextShared protocols are reviewed separately for each relevant tissue context.
Log every discrepancyCorrections remain explicit until they are implemented, tested and resolved.
Keep formal validation separatePrimary review does not replace independent consultant or pharmacy validation.
Local reviewer workspace: review records are stored in this browser on this device until you export them. Export the JSON validation log regularly and before clearing browser data or changing devices. Do not enter patient names, identifiers or clinical case data.
Validation overview
Progress is counted by tissue context so a shared regimen can be reviewed separately for each indication group.
Reviewer and record controls
Reviewer identity is stored only in the local validation log and exported files.
Local log ready
Governance boundary: completing a primary review record does not change the published clinical validation status of a regimen. Formal consultant oncology and oncology pharmacy validation remain separate controlled steps.
Tissue review plan
Select a tissue to work through its complete review queue.
Protocol review queue
Open a regimen, review each domain against the complete NCCP source and log any discrepancy before moving on.
NCCP protocol surveillance and clinical review
Know what is new, what changed and what still requires review
The NCCP Change Tracker shows whether each registered regimen is linked to the latest reviewed NCCP source, identifies new or changed protocols and makes the review state visible before any SACTCheck content is updated.
Core strength: clinicians can see what changed, why it may matter, whether it has been reviewed and which SACTCheck release incorporated the approved update.
1
DetectIdentify new or changed NCCP protocol sources.
2
ComparePresent the previous and current source together.
3
ReviewPrioritise possible treatment, safety and information changes.
4
ReconcileRecord the approved SACTCheck response and release.
Loading NCCP protocol statusPreparing protocol currency and review history.
Review workflow
A source change is a signal for review, not permission to update a clinical rule.
DetectNew or changed NCCP source identified
ComparePrevious and current content presented
ReviewClinical significance and required action recorded
ReconcileApproved update tested and linked to a SACTCheck release
What the tracker does and why each feature matters
Each capability is designed to improve source visibility, prioritisation and governance rather than replace clinical review.
What is new and what has changed
Detected changes remain visible until their review state is recorded.
NCCP protocol register
Every registered protocol is linked to its NCCP version, official source, review state and SACTCheck reconciliation history.
Governance boundary
The tracker supports surveillance and review. It does not independently determine whether a change is clinically correct, applicable or safe.
Required control: No detected change can modify a clinical rule automatically. A detected source change must be reviewed against the current NCCP PDF, reconciled with the encoded SACTCheck content, tested and approved before publication. The official NCCP protocol and local governance remain authoritative.
Protocol information and validation status
RegimenPACLitaxel monotherapy 80 mg/m²
NCCP code / version00226 / Version 9
ScheduleDays 1, 8, 15 and 22 — 28 days
Protocol review date14 April 2030
Source checkChecked against HSE PDF on 15 July 2026
Clinical validationPending consultant and oncology-pharmacy review
Boundary implementation: a platelet count of exactly 90 ×10⁹/L is assigned to the protocol row stating platelets ≥90. The subsequent row is implemented as 70 to <90 to avoid overlap.
Open source protocolAssessment context
Original / current dose
Protocol-indicated dose
Encoded rule coverage
Calculated hepatic ratios
Bilirubin
ALT
AST
Highest transaminase
Triggered protocol interpretation
Copyable assessment summary
Protocol information and validation status
RegimenFOLFOX-6 Modified Therapy — 14 day
NCCP code / version00209 / Version 10a
Tumour groupGastrointestinal
Protocol review date31 October 2030
Source checkChecked against HSE PDF on 15 July 2026
Clinical validationPending consultant and oncology-pharmacy review
Scope of this prototype: day-1 haematology and delayed-week nadirs, renal/hepatic impairment, DPD status, neuropathy, diarrhoea, stomatitis, laryngo-pharyngeal dysaesthesia and pulmonary warning symptoms. Any modification should be discussed with a Consultant.
Open source protocolAssessment context
Oxaliplatin
Bolus 5-FU
Infusional 5-FU
Component-specific protocol output
Oxaliplatin
Folinic acid
Bolus 5-FU
Infusional 5-FU
Triggered protocol interpretation
Copyable assessment summary
Protocol information and validation status
RegimenFOLFIRI Therapy — 14 day
NCCP code / version00227 / Version 9
Tumour groupGastrointestinal
Review date27 January 2030
Rule-pack statusAutomated tests complete; clinical review pending
Scope: haematology and delayed-week nadirs, DPD status, renal/hepatic impairment, diarrhoea and stomatitis.
Open source protocolContext
Irinotecan action
5-FU action
Assessment
Protocol information and URO status
RegimenCapecitabine and Oxaliplatin Therapy (XELOX)
NCCP code / version00321 / Version 9
ScheduleOxaliplatin day 1; capecitabine days 1–14; 21-day cycle
Review date11 November 2030
ArchitectureUniversal Regimen Object v1
ValidationAutomated prototype tests complete; clinical review pending
Oxaliplatin—
Capecitabine—
Assessment—
Protocol information
RegimenModified FOLFIRINOX
NCCP00515 · Version 7
IndicationMetastatic pancreatic adenocarcinoma
Clinical reviewPending consultant and oncology-pharmacy review
Clinical summary
Protocol information
RegimenGemcitabine and cisplatin
NCCP00383 · Version 8
IndicationAdvanced biliary tract cancer
Clinical reviewPending consultant and oncology-pharmacy review
Clinical summary
Protocol information
RegimenCisplatin and 5-FU chemoradiation — Herskovic
NCCP00460 · Version 4
IndicationOesophageal carcinoma treated with definitive chemoradiation
Clinical reviewPending consultant and oncology-pharmacy review
Clinical summary
Validate and preview a protocol JSON file
This validates the file locally in this browser. It does not upload patient information or permanently publish a protocol.
Use a reviewed SACTCheck schema 2.x protocol file.
This local preview checks file structure only. Clinical source review, oncology pharmacy review and release approval remain separate governance steps.
Awaiting file
Protocol—
Inputs—
Rules—
Validation—